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Daily Probiotic’s (Lactobacillus casei Shirota) Reduction 
of Infection Incidence in Athletes
Michael Gleeson, Nicolette C. Bishop, Marta Oliveira, and Pedro Tauler
The purpose of this study was to examine the effects of a probiotic supplement during 4 mo of winter training 
in men and women engaged in endurance-based physical activities on incidence of upper respiratory-tract 
infections (URTIs) and immune markers. Eighty-four highly active individuals were randomized to probiotic 
(n = 42) or placebo (n = 42) groups and, under double-blind procedures, received probiotic (PRO: Lactobacil-
lus casei Shirota [LcS]) or placebo (PLA) daily for 16 wk. Resting blood and saliva samples were collected 
at baseline and after 8 and 16 wk. Weekly training and illness logs were kept. Fifty-eight subjects completed 
the study (n = 32 PRO, n = 26 PLA). The proportion of subjects on PLA who experienced 1 or more weeks 
with URTI symptoms was 36% higher than those on PRO (PLA 0.90, PRO 0.66; p = .021). The number of 
URTI episodes was significantly higher (p < .01) in the PLA group (2.1 ± 1.2) than in the PRO group (1.2 
± 1.0). Severity and duration of symptoms were not significantly different between treatments. Saliva IgA 
concentration was higher on PRO than PLA, significant treatment effect F(1, 54) = 5.1, p = .03; this difference 
was not evident at baseline but was significant after 8 and 16 wk of supplementation. Regular ingestion of 
LcS appears to be beneficial in reducing the frequency of URTI in an athletic cohort, which may be related to 
better maintenance of saliva IgA levels during a winter period of training and competition.
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Probiotics are food supplements that contain live 
microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host. There is now 
a reasonable body of evidence that regular consumption of 
probiotics can modify the population of the gut microbiota 
and influence immune function (Borchers, Selmi, Meyers, 
Keen, & Gershwin, 2009; Gill & Cross, 2002; Matsu-
zaki, 1998; Mengheri, 2008; Minocha, 2009), although 
it should be noted that such effects are strain specific. 
Some studies suggest that increased resistance to enteric 
pathogens and promotion of antitumor activity occur with 
probiotic supplementation, and there is emerging evi-
dence that probiotics may be effective in alleviating some 
allergic and respiratory disorders in children (Hatakka 
et al., 2001; Kopp-Hoolihan, 2001). Furthermore, it has 
been reported that probiotic supplementation enhances 
host resistance to upper respiratory-tract infection (URTI) 
in the general population (de Vrese et al., 2006).
It might be expected that potential benefits of probi-
otics for human health, in particular reducing infection 
incidence, are likely to be greater in individuals with 
decreased immune function or known susceptibility to 
common infections, such as HIV patients and the elderly. 
There is currently a lack of information on the effects of 
probiotics in a healthy but marginally immunocompro-
mised human population. Prolonged intense exercise has 
been associated with a transient depression of immune 
function (Gleeson, 2005, 2007), and a heavy training and 
competition schedule can lead to immune impairment in 
athletes. This is associated with an increased susceptibil-
ity to URTI (Bishop, 2005; Fahlman & Engels, 2005; 
Gleeson et al., 1999; Nieman, Johanssen, Lee, & Ara-
batzis, 1990; Peters & Bateman, 1983). Probiotic intake 
might help reduce the incidence of infection in athletes 
by improving immune function; there is some limited 
evidence to support this (West, Pyne, Peake, & Cripps, 
2009). A substantial proportion of runners and triathletes 
also report gastrointestinal (GI) problems (e.g., abdomi-
nal discomfort, diarrhea) during long-distance training 
runs or competitive events (Simons & Kennedy, 2004). 
Probiotics could possibly have a beneficial effect in pre-
venting such symptoms in these individuals by improving 
gut-barrier function (Collado, Isolauri, Salminen, & Sanz, 
2009; Kekkonen et al., 2007; Mengheri, 2008).
To date, there are very few published studies on the 
effectiveness of probiotic use in athletes. Cox, Pyne, 
Saunders, and Fricker (2010) showed that during the 
winter months athletes (N = 20) suffered fewer days 
of respiratory illness and lower severity of respiratory-
illness symptoms when taking a daily probiotic (Lacto-
bacillus fermentum). However, that study had a small 
International Journal of Sport Nutrition and Exercise Metabolism, 21, 2011, 55-64
© 2011 Human Kinetics, Inc.
Gleeson, Bishop, and Oliveira are with the School of Sport, 
Exercise and Health Sciences, Loughborough University, 
Loughborough, UK. Tauler is with the Dept. of Fundamental 
Biology and Health Sciences, University of the Balearic Islands, 
Palma de Mallorca, Spain.
56  Gleeson et al.
number of subjects, and illness symptoms were only 
recorded over a 4-week period.
The aims of the current study were to examine the 
effects of 4 months of daily oral supplementation with 
a commercially available fermented milk drink contain-
ing the gram-positive probiotic L. casei Shirota (LcS) 
on infection incidence and selected markers of immune 
function in a cohort of university-based endurance ath-
letes during a period of winter training and competition. 
We chose to examine this particular probiotic because it 
is one of the most popular commercially available pro-
biotics available worldwide, and there is strong evidence 
that the bacteria it contains survive GI transit, modify 
the gut microbiota population (Matsumoto et al., 2006; 
Spanhaak, Havenaar, & Schaafsma, 1998), and can alter 
some aspects of systemic immunity in humans (Matsu-
zaki, 1998; Nagao, Nakayama, Muto, & Okumura, 2000; 
O’Connell, Allgrove, Pollard, Xiang, & Harbige, 2010).
Methods
Subjects
Eighty-four healthy subjects who were engaged in regular 
sports training (predominantly endurance-based activi-
ties such as running, cycling, swimming, triathlon, team 
games, and racquet sports) volunteered to participate 
in the study. They ranged from recreationally active to 
Olympic triathletes, and their self-reported training loads 
averaged 10 hr/week. Subjects were required to complete 
a comprehensive health-screening questionnaire before 
starting the study and to not have taken any medication in 
the 4 weeks before the study. All subjects recruited to the 
study confirmed that they had not taken any probiotic in 
the previous 4 months. All subjects were fully informed 
about the rationale for the study and of all experimental 
procedures to be undertaken. Subjects provided written 
consent to participate in the study, which had earlier 
received the approval of Loughborough University’s 
ethical advisory committee. Subjects were enrolled after 
having fulfilled all inclusion criteria and presenting none 
of the exclusion criteria (determined by both question-
naire and interview).
Subjects could be included if they were currently 
healthy, had been involved in endurance training for at 
least 2 years, engaged in at least three sessions and at 
least 3 hr of moderate- to high-intensity training time per 
week, and were 18–55 years of age. Subjects presenting 
one or more of the following criteria were excluded from 
participation: smoking or use of any medication; currently 
taking probiotic supplements; suffered from or had a his-
tory of cardiac, hepatic, renal, pulmonary, neurological, 
GI, hematological, or psychiatric illness; objected to the 
prescription of diet (abstinence from fermented milk 
products other than the daily supplement).
A total of 84 healthy individuals were recruited as 
subjects and were randomly assigned to one of two treat-
ments with stratification by gender only; under double-
blind procedures 42 subjects received the probiotic and 
42 received the placebo. Of these 84 subjects, 30 were 
female and 54 were male, with a mean age at recruitment 
of 27.0 ± 11.6 years (M ± SD). Sample-size estimation of 
32 subjects per treatment group was based on an expected 
rate of 2.0 ± 1.0 URTI episodes (M ± SD) during the 
winter months (Neville, Gleeson, & Folland, 2008), a 
target 30% reduction in number of episodes, statistical 
power of 80%, and a Type I error of 5%. We initially 
recruited 84 volunteers to account for an estimated 30% 
dropout rate over the study period.
First Visit
For the first visit to the laboratory, subjects arrived in 
the morning at 8:30–10:30 a.m. after an overnight fast 
of approximately 12 hr. They were asked to empty their 
bladder before body mass and height were recorded. 
Information about the study was given to them, and they 
then signed an informed-consent form. They then sat qui-
etly for 10 min and completed a health-screen question-
naire and inclusion- and exclusion-criteria questionnaire 
before providing an unstimulated saliva sample by passive 
dribble into a sterile collection tube. Saliva samples were 
stored frozen at –80 °C before analysis. Subsequently, 
a resting venous blood sample (11 ml) was obtained 
by venipuncture from an antecubital forearm vein into 
two Vacutainer tubes (Becton Dickinson, Oxford, UK) 
containing either K3EDTA or heparin. Hematological 
analysis was immediately carried out on the EDTA 
sample (including hemoglobin, hematocrit, and total 
and differential leukocyte counts) using an automated 
cell counter (Ac.T5diff hematology analyzer, Beckman 
Coulter, High Wycombe, UK). Provided that subjects met 
the criteria for inclusion in the study, they were randomly 
assigned to the treatment or placebo group and asked to 
start taking the supplement the next day.
Study Intervention
Probiotic and placebo supplements were supplied as fer-
mented milk in sealed pots of 65 ml with date-stamped 
expiration. The probiotic drink contained a minimum of 
6.5 × 109 live cells of LcS in each pot. The placebo was 
identical in taste and color to the probiotic but contained 
no LcS. The supplements were stored at 4–7 °C (domestic 
refrigerator). Subjects returned to the laboratory every 
2–3 weeks to receive a fresh supply of supplement. A 
compliance log of sample collection was taken. Subjects 
consumed the supplement twice per day, one 65-ml pot 
taken with breakfast and one with the evening meal, for 
16 weeks. They were asked to keep a record of any days 
when they missed taking the supplement.
Study Protocol
During the 4-month intervention period subjects were 
asked to continue with their normal training programs. 
Consumption of supplements (vitamins and minerals, 
etc.), additional probiotics, or any fermented dairy 
products (e.g., yogurt, sour cream, crème fraiche) was 
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not permitted during this period. Subjects completed a 
health questionnaire (URTI symptoms and GI-discomfort 
symptoms) on a weekly basis. They were not required to 
abstain from medication when they were suffering from 
illness symptoms, but they were required, on a weekly 
basis, to report any unprescribed medications taken, visits 
to the doctor, and any prescribed medications.
The illness symptoms listed on the questionnaire 
were sore throat, inflammation in the throat, runny nose, 
cough, repetitive sneezing, fever, persistent muscle sore-
ness, joint aches and pains, weakness, headache, and loss 
of sleep. The nonnumerical ratings of light, moderate, 
and severe (L, M, or S, respectively) were scored as 1, 
2, and 3, respectively, to provide a quantitative means of 
data analysis (Fricker et al., 2005), and the total symp-
tom score for every subject each week was calculated 
by multiplying the total number of days each symptom 
was experienced by the numerical ratings of L, M, or S 
symptoms of 1, 2 or 3, respectively. In any given week 
a total symptom score ≥12 was taken to indicate that a 
URTI was present. This score was chosen because to 
achieve it a subject would have to record at least three 
moderate symptoms lasting for 2 days or two moderate 
symptoms lasting for at least 3 days in a given week. A 
single URTI episode was defined as a period during which 
the weekly total symptom score was ≥12 and separated by 
at least 1 week from another week with a total symptom 
score ≥12. Subjects were also asked to rate the impact of 
illness symptoms on their ability to train (normal training 
maintained, training reduced, or training discontinued; 
L, M, or S, respectively).
The GI-discomfort symptoms listed on the question-
naire were loss of appetite, stomach upset, vomiting, 
abdominal pain, and diarrhea. These symptoms were 
rated and scored the same way as the illness symptoms. 
Subjects were also asked to fill in a standard short-form 
International Physical Activity Questionnaire (http://
www.ipaq.ki.se/downloads.htm) at weekly intervals, thus 
providing quantitative information on training loads in 
metabolic-equivalent (MET) hr/week (Craig et al., 2003).
After 8 and 16 weeks subjects came to the labora-
tory again after an overnight fast. They were required to 
abstain from any strenuous physical activity for 24 hr 
before coming to the laboratory. During these visits body 
mass was recorded and an unstimulated saliva sample and 
venous blood samples were collected as described for the 
first visit to the laboratory.
Blood Cell Counts
Blood samples in the K3EDTA Vacutainer (4 ml) were 
used for hematological analysis using an automated cell 
counter (Ac.T5diff hematology analyzer, Beckman Coul-
ter, High Wycombe, UK). The intra-assay coefficient of 
variation for all measured variables was less than 3.0%.
Plasma Immunoglobulins
The remaining blood in the K3EDTA tube was centri-
fuged at 1,500 g for 10 min at 4 °C within 10 min of 
sampling. The plasma obtained was immediately stored at 
–80 °C before analysis of immunoglobulins A, G, and M 
(immunoturbidometric assay on Pentra 400 autoanalyzer, 
Horiba, France, using the manufacturer’s calibrators and 
controls). The intra-assay coefficients of variation for 
immunoglobulins A, G, and M were 3.2%, 1.9%, and 
2.3%, respectively.
Lymphocyte Subsets
Lymphocyte subsets CD3, CD4, CD8, CD19, and CD56 
to enumerate total T cells, T-helper cells, T-cytotoxic 
cells, B cells, and NK cells, respectively, were determined 
by three-color flow cytometry (Becton Dickinson FACS-
Calibur) with CellQuest software (Becton Dickinson 
Biosciences, Oxford, UK) as described previously (Lan-
caster et al., 2004). Forward-scatter versus side-scatter 
plots were used to gate on the lymphocyte population 
by morphology, and 10,000 lymphocyte events were 
acquired per analysis. Estimations of the absolute CD3+, 
CD3+CD4+, CD3+CD8+, NK cell (CD3-CD56+), and B 
cell (CD3-CD19+) numbers were derived from the total 
lymphocyte count.
Antigen-Stimulated Cytokine Production
Stimulated whole-blood-culture production of cytokines 
(interferon [IFN]-γ, tumor-necrosis factor-α, interleukin 
[IL]-1β, IL-2, IL-4, IL-6, IL-8, IL-10, and macrophage 
chemoattractant protein-1) was determined as follows: 
2 ml of heparinized whole blood were added to 2 ml of 
RPMI medium (Sigma Chemicals, Poole, UK) with added 
stimulant at a dilution of 1:4,000. The stimulant was a 
commercially available multiantigen vaccine (Pediacel 
Vaccine, Sanofi Pasteur, UK) containing diphtheria, 
tetanus, acellular pertussis, poliomyelitis, and hemophilus 
influenzae Type b antigens. Whole blood was cultured 
at 37 °C and 5% CO2 for 24 hr. After centrifugation at 
1,500 g for 10 min at 4 °C, supernatants were collected 
and stored frozen at –80 °C before analysis of cytokine 
concentrations using an Evidence Investigator System 
and the cytokine biochip array EV3513 (Randox, County 
Antrim, UK).
Saliva IgA
Duplicate saliva samples were analyzed for secretory IgA 
using an ELISA kit (Salimetrics, Philadelphia, PA). The 
intra-assay coefficient of variation for IgA was 10.1%.
Statistical Analysis
The difference in proportion of subjects who presented 
with symptoms of infection during the trial between the 
probiotic and placebo groups was assessed by chi-square 
test. Comparisons of the proportion of days or weeks with 
infection symptoms were also assessed with a chi-square 
test. For the total symptom-severity score and the mean 
duration of infection symptoms of subjects with infection 
symptoms, comparisons between the treatments for single 
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measurements were made using independent (unpaired) 
t tests. Changes in saliva and blood variables during the 
study were analyzed using a two-factor (Treatment × 
Time) between- and within-subjects ANOVA with repeated 
measures (time: 0, 8, and 16 weeks of intervention). Cor-
responding assumptions of homogeneity of variances and 
intercorrelation were checked, as was sphericity in the data. 
Any significant F ratios subsequently shown were assessed 
using Student’s paired t tests with Holm–Bonferroni cor-
rection for multiple comparisons applied to the unadjusted 
p value. The observed powers of the reported main and 
interaction effects were all greater than .8. Partial eta-
squared values were assessed to estimate the effect size 
of any statistically significant differences found. Using 
guidelines of Cohen (1988), .01 = small effect, .06 = mod-
erate effect, and .14 = large effect. Statistical significance 
was accepted at p < .05. Data are expressed as M ± SD.
Results
Adherence to the Study
Of the 84 subjects, 65 successfully completed 8 weeks of 
the study and 58 subjects completed the full 16 weeks. 
Several subjects withdrew because they could not take 
the liquid supplement with them to competitions to which 
they had to travel by air. Others withdrew because of 
injury or persistent illness (preventing them from per-
forming training) or for undisclosed reasons. Adherence 
to the intervention was good: Subjects who completed 
the study reported that they missed taking the supplement 
on average only on 3 days (range 0–12 days). Saliva and 
blood samples were obtained on all three visits from 
53 subjects, although sufficient blood volume to allow 
analyses of all variables was only obtained from 49 sub-
jects. Subjects were asked at the end of the study which 
treatment they thought they were on. Sixty percent said 
they did not know, 23% thought they were on probiotic, 
and 17% thought they had taken placebo. Of the subjects 
who expressed an opinion, 43% were correct in their 
selection of treatment and 57% were incorrect. Hence, 
the study blinding was effective.
The baseline characteristics of the probiotic subjects 
(n = 32) who completed the study were as follows: age 32 
± 14 years, body mass 71.2 ± 9.9 kg, height 175 ± 9 cm, 
body-mass index 23.2 ± 2.8 kg/m2, and self-reported 
weekly training load 8.7 ± 4.1 hr/week. The baseline 
characteristics of the placebo subjects (n = 26) were as 
follows: age 25 ± 9 years, body mass 71.6 ± 10.7 kg, 
height 175 ± 8 cm, body-mass index 23.3 ± 2.5 kg/m2, 
and self-reported weekly training load 9.3 ± 3.8 hr/week. 
There were no statistically significant differences between 
the two treatment groups.
Training Loads
Analysis of the International Physical Activity Ques-
tionnaire indicated that the weekly training loads were 
relatively stable between and within experimental groups 
over the 16 weeks of the study (Figure 1) and that the 
means were not significantly different for the probiotic 
and placebo groups: 62.6 ± 32.2 and 62.6 ± 32.6 MET-hr/
week, respectively (p = .784). This is equivalent to about 
10 hr of moderate to vigorous activity per week.
Infection-Symptom Incidence
Analysis of the URTI-symptom questionnaires indicated 
that 18 ± 7% of the cohort experienced a URTI episode 
each week. Fifteen subjects did not experience a single 
URTI episode during the study period, and 50 subjects 
experienced at least one. The proportion of subjects on 
placebo who experienced one or more weeks with URTI 
symptoms was higher than that of those on probiotic 
(placebo .90, probiotic .66; p = .021). The proportion 
of weeks that subjects suffered URTI symptoms was 
Figure 1 — Training loads in metabolic-equivalent (MET) hr/week over the 16-week study period for subjects who completed the 
study, M ± SD. PLA = placebo; PRO = probiotic. No statistically significant difference between treatments.
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significantly higher in the placebo group than in the 
probiotic group (.23 and .12, respectively; p < .001). 
Furthermore, the proportion of weeks that subjects 
took medication was also significantly higher in the 
placebo group than in the probiotic group (.17 and .10, 
respectively; p < .01).
The mean number of URTI-symptom weeks (probi-
otic 1.9 ± 1.5, placebo 3.5 ± 2.0; p < .01) and the mean 
number of URTI episodes (probiotic 1.2 ± 1.0, placebo 
2.1 ± 1.2; p < .01) were ~50% lower on probiotic than 
placebo.
Severity and Mean Duration  
of URTI Symptoms
When a URTI episode was present, the mean total 
 symptom-severity score (probiotic 49 ± 55, placebo 50 
± 32; p = .928) and duration of symptoms (probiotic 7.9 
± 5.5 days, placebo 7.6 ± 3.2 days; p = .801) were not 
significantly different between treatments. However, 
the proportion of subjects who stated that training was 
negatively affected when they suffered URTI symptoms 
was lower on probiotic than on placebo (.54 and .81, 
respectively; p = .036). When a URTI episode was  present, 
the proportion of subjects who took medication was 
similar in the probiotic and placebo groups (.74 and .78, 
respectively), and the proportion of subjects who visited 
their doctor was also similar in the probiotic and placebo 
groups (.26 and .19, respectively).
Incidence of GI-Discomfort Symptoms
The proportion of subjects on placebo who experienced 
1 or more weeks with GI-discomfort symptoms was not 
significantly different than for those on probiotic (.57 
and .54, respectively). However, the proportion of days 
that subjects suffered GI-discomfort symptoms, though 
low in both groups, was 33% higher in the placebo group 
than in the probiotic group (.03 and .02, respectively; p = 
.008). During weeks when one or more GI-discomfort 
symptoms were present, the mean total symptom-severity 
score (probiotic 9 ± 4, placebo 12 ± 4; p = .444) and 
duration of symptoms (probiotic 4.2 ± 3.8 days, placebo 
5.9 ± 3.9 days; p = .410) were not significantly different 
between treatments.
Plasma and Saliva Immunoglobulins
There were no significant time, treatment, or interac-
tion effects for plasma concentrations of IgA and IgM 
(Table 1). Although there was significant interaction for 
plasma IgG, F(2, 40) = 3.9, p = .029, η2 = .16, and plasma 
total Ig, F(2, 40) = 3.4, p = .045, η2 = .14, post hoc tests 
did not reveal significant differences between treatments 
at any time point. Saliva IgA concentration was higher 
with probiotic than placebo—main effect for treatment 
F(1, 54) = 5.1, p = .03, η2 = 0.09; this difference was 
not evident at baseline but was significant after 8 and 16 
weeks of supplementation (Figure 2).
Blood Leukocyte Counts and Lymphocyte 
Subsets
There were no significant time, treatment, or interaction 
effects for blood total or differential leukocyte counts 
(Table 2), apart from monocyte counts, which were 
slightly lower with probiotic than placebo—main effect 
of treatment F(1, 43) = 4.2, p = .047, η2 = .09. There were 
no significant time, treatment, or interaction effects for 
any of the blood lymphocyte subsets (Table 2).
Table 1 Plasma IgA, IgG, IgM, and Total Ig (g/L) Before and After 8 and 16 Weeks  
of the Intervention Period
Before 8 weeks 16 weeks
p, interaction,
time, treatment Post hoc
IgA .241, .098, .095
 placebo 1.85 (0.97) 0.06 (–0.04 to 0.16) –0.05 (–0.13 to 0.03)
 probiotic 2.30 (0.65) –0.03 (–0.10 to 0.04) –0.04 (–0.13 to 0.05)
IgG .029*, .312, .816 *n.s.
 placebo 10.9 (1.4) 0.6 (0.0–1.2) 0.3 (–0.1 to 0.7)
 probiotic 11.4 (2.3) –0.1 (–0.3 to 0.1) 0.1 (–0.2 to 0.4)
IgM .310, .306, .356
 placebo 1.23 (0.61) 0.03 (–0.03 to 0.09) 0.01 (–0.04 to 0.06)
 probiotic 1.10 (0.35) 0.03 (–0.06–0.12) –0.03 (–0.12 to 0.06)
Total Ig .045*, .240, .558 *n.s.
 placebo 14.0 (1.9) 0.6 (–0.1 to 0.13) 0.3 (–0.1 to 0.7)
 probiotic 14.8 (2.6) –0.1 (–0.4 to 0.2) –0.2 (–0.6 to 0.2)
Note. Baseline values before supplementation are expressed as M (SD); n = 25 probiotic, n = 20 placebo. The values shown at 8 and 16 weeks of 
supplementation are the mean change (with 95% confidence limits) from baseline. These data are from the subjects who completed the study and 
for whom blood samples were obtained on all three visits.
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Stimulated Whole-Blood-Culture Cytokine 
Production
There were no significant time, treatment, or inter-
action effects for whole-blood-culture production of 
IL-10 (Table 3). For all the other cytokines there were 
no significant interactions or main effects of treatment, 
but there were significant effects of time, with cytokine 
production being higher at baseline than at 8 weeks and 
16 weeks (IL-2, IL-4, IL-6, IL-8, and tumor-necrosis 
factor-α) or only at 16 weeks (IL-1β, IFN-γ, and macro-
phage chemoattractant protein-1; p < .01 for all except 
IFN-γ, where p < .05; η2 > .14 for all).
Discussion
The main findings of the current study were that the pro-
portion of subjects who experienced 1 or more weeks with 
URTI symptoms was 27% lower and the average number 
of URTI episodes was 50% lower in the probiotic group 
than in the placebo group. The severity and duration of 
symptoms were not significantly different on probiotic 
than with placebo, but training was less affected when 
URTI was present for the probiotic group than the placebo 
group. These positive clinical consequences provide evi-
dence for the beneficial effects of daily LcS ingestion in a 
cohort of highly physically active people. The proportion 
of subjects from the placebo group who experienced 1 
or more weeks with GI-discomfort symptoms was not 
significantly different from the probiotic group, but the 
proportion of days that subjects suffered these symptoms 
was 33% lower with probiotic than placebo, which can 
be seen as another benefit of this nutritional intervention 
for an athlete cohort.
Some emerging evidence from recent studies sug-
gests that probiotics can be effective in preventing not 
only GI infections (Gill & Prasad, 2008; Minocha, 
2009) but also respiratory infections. For example, 
administration of Lactobacillus GG to children in day 
care centers decreased the incidence of URTI (Hatakka 
et al., 2001). In several recent large-scale human studies 
it has been demonstrated that regular, long-term intake 
of various probiotic-prebiotic combinations improved 
health by reducing both the incidence and the sever-
ity of respiratory diseases during the winter season 
(Pregliasco et al., 2008; Winkler, de Vrese, Laue, & 
Schrezenmeir, 2005). Other studies have reported that 
probiotics are associated with shortened duration of 
common cold symptoms and reduced severity of symp-
toms without an effect on infection incidence in adults 
during winter-to-spring periods (de Vrese et al., 2006; 
Guillemard, Tondu, Lacoin, & Schrezenmeir, 2009).
There is now substantial evidence that a few 
months of oral probiotic supplementation can modu-
late systemic immune functions (de Vrese et al., 2006; 
Gill & Prasad, 2008; Kim, Park, Cho, Paik, & Park, 
2006; Miettinen, Vuopio-Varkila, & Varkila, 1996; 
Olivares et al., 2006; Winkler et al., 2005). Probiotics 
influence immunity by interacting with receptors on 
intestinal epithelial cells, M cells, and dendritic cells 
in the GI tract and with the common mucosal immune 
system, an interconnected system that links the Peyer’s 
patches in the GI tract to effector sites on the mucosa 
in the GI tract and beyond in the upper respiratory and 
urogenital tracts (Kudsk, 2002). Several studies have 
demonstrated the ability of regular ingestion of LcS 
to modulate the healthy human gut microbial popula-
tion and to induce some immune changes, including 
Figure 2 — Saliva IgA concentration before and after 8 and 16 weeks of the study for the subjects who completed the study and 
for whom saliva samples were obtained on all three visits (PRO n = 32, PLA n = 24), M ± SD. Saliva IgA concentration was higher 
on PRO than PLA, significant trial effect F(1, 54) = 5.1, p = .03; this difference was not evident at baseline but was significant after 
8 and 16 weeks of supplementation (*p < .05; **p < .01). PLA = placebo; PRO = probiotic. #p < .05 versus Week 0.
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Table 2 Blood Cell Counts Before and After 8 and 16 Weeks of the Intervention Period
Before 8 weeks 16 weeks
p, interaction,
time, treatment Post hoc
Leukocytes
 Leukocytes (cells × 109/L) .651, .836, .275
  placebo 6.1 (1.6) –0.1 (–0.9 to 0.7) –0.3 (–1.0 to 0.4)
  probiotic 5.6 (1.4) –0.1 (–0.4 to 0.6) 0.1 (–0.8 to 0.9)
 Neutrophils (cells × 109/L) .727, .594, .484
  placebo 3.2 (1.2) –0.2 (–0.9 to 0.5) –0.2 (–0.9 to 0.5)
  probiotic 2.8 (1.3) –0.1 (–0.4 to 0.6) 0.2 (–0.7 to 1.1)
 Monocytes (cells × 109/L) .480, .144, .047*
*probiotic 
< placebo
  placebo 0.48 (0.18) 0.07 (–0.03 to 0.17) 0.06 (–0.04 to 0.16)
  probiotic 0.44 (0.15) 0.00 (–0.05 to 0.05) 0.01 (–0.05 to 0.07)
 Lymphocytes (cells × 109/L) .957, .057, .576
  placebo 2.00 (0.72) 0.17 (–0.03 to 0.38) 0.07 (–0.22 to 0.32)
  probiotic 1.92 (0.50) 0.14 (–0.01 to 0.29) 0.07 (–0.12 to 0.26)
Lymphocyte Subsets
 T cells CD3+ (cells × 109/L) .889, .138, .656
  placebo 1.23 (0.54) 0.09 (–0.14 to 0.32) 0.00 (–0.21 to 0.21)
  probiotic 1.17 (0.35) 0.12 (0.01–0.23) 0.00 (–0.14 to 0.14)
 T-Helper cells CD3+CD4+ 
(cells × 109/L) .709, .066, .365
  placebo 0.72 (0.27) 0.05 (–0.04 to 0.14) 0.00 (–0.12 to 0.12)
  probiotic 0.63 (0.15) 0.09 (0.01–0.17) 0.04 (–0.05 to 0.13)
 T-cytotoxic cells 
CD3+CD8+ (cells × 109/L) .927, .038*, .910 *n.s.
  placebo 0.45 (0.27) 0.09 (–0.03 to 0.21) 0.01 (–0.07 to 0.09)
  robiotic 0.45 (0.25) 0.07 (0.0–0.14) 0.01 (–0.08 to 0.10)
 B cells CD3–CD19+  
(cells x 109/L) .130, .742, .932
  placebo 0.24 (0.13) –0.02 (–0.04 to 0.0) –0.02 (–0.06 to 0.2)
  probiotic 0.21 (0.10) 0.03 (0.01–0.05) 0.02 (0.00–0.04)
 Natural killer cells CD3–
CD56+ (cells × 109/L) .354, .076, .432
  placebo 0.23 (0.17) 0.04 (–0.02 to 0.10) 0.01 (–0.03 to 0.05)
  probiotic 0.23 (0.14) –0.01 (–0.06 to 0.04) –0.03 (–0.07 to 0.01)
Note. Baseline values before supplementation are expressed as M (SD); n = 25 probiotic, n = 20 placebo. The values shown at 8 and 16 weeks of 
supplementation are the mean change (with 95% confidence limits) from baseline. These data are from the subjects who completed the study and 
for whom blood samples were obtained on all three visits. 
stimulation of Th1 cellular immune responses and NK 
cell cytolytic activity (Matsuzaki, 1998; Nagao et al., 
2000) and increases in saliva IgA secretion (O’Connell 
et al., 2010).
Although in the current study regular LcS ingestion 
was associated with lower URTI incidence, we could 
not directly attribute this to any specific improvement of 
immune function, because supplementation with LcS for 
16 weeks did not substantially alter circulating leukocyte, 
neutrophil, lymphocyte, monocyte, or lymphocyte 
subset numbers; plasma immunoglobulins; or antigen-
stimulated whole-blood-culture cytokine production. 
The data on saliva IgA suggest the possibility that LcS 
supplementation helped maintain saliva IgA concentra-
tion compared with placebo during a period when some 
aspects of immune function (saliva IgA in the placebo 
group and antigen-stimulated cytokine production in 
both groups) were decreased. Note that in both athlete 
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Table 3 Stimulated Whole-Blood-Culture Cytokine Production Before and After 8 and 16 Weeks  
of the Intervention 
Before 8 weeks 16 weeks
p, interaction,
time, treatment Post hoca
Interleukins
 IL-1β (pg/ml) .673, .001*, .583 *1 > 3, p < .001
  placebo 9.8 (7.8) –1.0 (–6.5 to 4.5) –3.8 (–7.9 to 0.3)
  probiotic 9.8 (8.9) –3.5 (–7.3 to 0.3) –4.5 (–6.3 to 2.7)
 IL-2 (pg/ml) .540, .001*, .166
*1 > 2, 1 > 3; 
both p < .001
  placebo 167 (189) –72 (–114 to 30) –105 (–190 to 20)
  probiotic 108 (127) –63 (–116 to 10) –60 (–107 to 13)
 IL-4 (pg/ml) .415, .018*, .305
*1 > 2, p < .01;
1 > 3, p < .05125
  placebo 4.0 (4.4) –1.5 (–3.2 to 0.2) –1.8 (–3.9 to 0.3)
  probiotic 2.9 (2.4) –0.9 (–1.6 to 0.2) –0.7 (–1.4 to 0.0)
 IL-6 (pg/ml) .488, .001*, .550
*1 > 2, 1 > 3; 
both p < .01
  placebo 158 (126) –35 (–77 to 7) –94 (–152 to 35)
  probiotic 187 (130) –71 (–119 to 23) –97 (–157 to 37)
 IL-8 (pg/ml) .599, .001*, .737
*1 > 2, 1 > 3; 
both p < .01
  placebo 1,193 (656) –372 (–629 to 115) –294 (–739 to 151)
  probiotic 1,355 (602) –473 (–786 to 160) –522 (–854 to 190)
 IL-10 (pg/ml) .125, .070, .345
  placebo 3.6 (2.6) 0.6 (–1.8 to 3.0) –1.0 (–2.3 to 0.3)
  probiotic 3.9 (4.3) –2.1 (–3.4 to 0.8) –1.5 (–3.0 to .0)
Other Cytokines
 IFN-γ (pg/ml) .414, .036*, .476 1 > 3, p < .05
  placebo 19.7 (14.2) –6.2 (–12.5 to 0.1) –9.2 (–14.9 to 3.5)
  probiotic 23.8 (34.5) –8.1 (–18.7 to 2.5) –6.3 (–15.4 to 2.8)
 TNF-α (pg/ml) .150, .002*, .674
1 > 2, p < .05;
1 > 3, p < .001
  placebo 21.7 (17.4) –4.1 (–13.3 to 5.1) –11.6 (–20.6 to 2.6)
  probiotic 23.7 (27.0) –14.1 (–24.1 to 4.1) –13.0 (–22.7 to 3.3)
 MCP-1 (pg/ml) .391, .001*, .878 1 > 3, p < .001
  placebo 778 (155) –114 (–145 to 17) –34 (–153 to 85)
  probiotic 820 (69) –230 (–346 to 114) –63 (–143 to 17)
Note. IFN = interferon; TNF = tumor-necrosis factor; MCP = macrophage chemoattractant protein. Baseline values before supplementation are 
expressed as M (SD); n = 25 probiotic, n = 20 placebo. The values shown at 8 and 16 weeks of supplementation are the mean change (with 95% confi-
dence limits) from baseline. These data are from the subjects who completed the study and for whom blood samples were obtained on all three visits.
a1 = before; 2 = 8 weeks; 3 = 16 weeks.
and nonathlete populations, falls in saliva IgA have been 
associated with increased infection incidence (Fahlman & 
Engels, 2005; Gleeson et al., 1999; Neville et al., 2008). 
Alternatively, LcS supplementation could have caused an 
improvement in another aspect of immune function that 
we did not measure. In the current study we observed that 
antigen-stimulated whole-blood production of several 
cytokines decreased from baseline after 8 or 16 weeks of 
intervention with both probiotic and placebo treatments. 
It is not clear whether this observation represents a sea-
sonal effect or an accumulation of training-stress effect.
A few recent probiotic intervention studies in athletes 
have provided evidence of apparent health benefit, with 
reports of fewer days of respiratory illness and lower 
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severity of respiratory-illness symptoms (Cox et al., 2010; 
West, Pyne, Hopkins, et al., 2009) and shortened duration 
of GI-upset episodes (Kekkonen et al., 2007) when taking 
a daily Lactobacillus probiotic. Possible mechanisms 
appear to include higher spontaneous IFN-γ production 
(Cox et al., 2010) and improved maintenance of salivary 
IgA levels (Tiollier et al., 2007) during periods of physi-
cal stress. West, Pyne, Hopkins, et al. (2009) recently 
reported that probiotic supplementation (L. fermentum) in 
a cohort of 64 male and 35 female elite endurance athletes 
was associated with a lower symptom load for chest infec-
tions and less use of cold and flu medications in males 
taking the probiotic compared with placebo, although 
differences in clinical outcomes between females in the 
two groups were not evident. In the current study there 
were more men than women in the cohort, and this may 
be another reason for the positive clinical outcome. In the 
current study there was no statistically significant differ-
ence in symptom severity or duration of URTI episodes 
with probiotic compared with placebo. However, this 
was not surprising given that we did not disallow oral 
medication when subjects experienced illness symptoms, 
and the proportion of subjects who took medication was 
similar in the probiotic and placebo groups (.74 and .78, 
respectively).
In summary, regular ingestion of LcS appears to 
be beneficial in preventing URTI in an athlete cohort, 
and training was less affected in the probiotic group 
when URTI was present. Regular ingestion of LcS 
also reduced the proportion of days that subjects suf-
fered GI-discomfort symptoms. We could not directly 
attribute these health benefits to any specific alteration 
of systemic immune function because no substantial 
differences in any of the circulating immune variables 
measured were detected in probiotic compared with 
placebo, and there were no positive changes in the pro-
biotic group at 8 or 16 weeks of intervention compared 
with Week 0 (baseline). The most likely possibilities 
are that LcS supplementation helped maintain saliva 
IgA concentration or had a positive impact on NK cell 
function.
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